Why Labcorp Holdings Inc. (LH) stock moved
Labcorp Holdings Inc. (LH) shares climbed 8.8% to $360.25 as of October 29, 2026, a significant gain from the prior close of $331.17. BestStocks flagged the session as a major change for LH. Below, we break down what changed for LH, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
LH climbed 8.8% to $360.25
LH climbed 8.8% in its latest session, moving from $331.17 to $360.25.
What it means for Labcorp Holdings Inc. investors
For Labcorp Holdings Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Strong 8.8% price move with conviction. Weighing against that: Labcorp fell 3.06% to $311.26 despite reaffirming full-year 2026 guidance and providing a long-term outlook through 2029 with 5–8% compound annual revenue growth and 8.5–11.5% adjusted EPS growth at its investor day on September 10 (PR Newswire); New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $360.75, implying +0.1% upside from $360.25. BestStocks rates the overall signal quality medium (71/100). With earnings roughly 110 days out, the next report is the most likely near-term test of the move.
LH price reaction
LH last traded at $360.25, up $29.08 (+8.78%) from the previous close of $331.17. The session traded on 2.5× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $304.60 and $360.25, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Labcorp Holdings Inc. (LH)
The consensus analyst price target on Labcorp Holdings Inc. (LH) is $360.75, 0.1% above the recent $360.25. Over the past 90 days analysts logged 0 upgrades, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LH line up.
The bullish case
- Wall Street's consensus price target of $360.75 implies +0.1% upside from $360.25.
- The Street's most bullish target is $410.00 (+13.8%).
- Earnings beat with positive market reaction.
- Strong 8.8% price move with conviction.
- Volume 2.5x average — institutional conviction.
The bearish case
- The most bearish analyst target is $306.00 (-15.1%).
- Labcorp fell 3.06% to $311.26 despite reaffirming full-year 2026 guidance and providing a long-term outlook through 2029 with 5–8% compound annual revenue growth and 8.5–11.5% adjusted EPS growth at its investor day on September 10 (PR Newswire).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for LH
In-depth LH event analyses
Frequently asked questions about LH
Why did Labcorp Holdings Inc. (LH) stock move?
LH climbed 8.8% to $360.25. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did LH stock rise?
LH gained 8.78% ($29.08) versus the prior close of $331.17, last trading at $360.25 on 2.5× average volume.
When is Labcorp Holdings Inc.'s next earnings date?
LH's next earnings report is estimated for 2027-02-16 — about 110 days away.
What is the analyst price target for LH?
The consensus analyst price target for LH is $360.75, about 0.1% above the current $360.25. Over the past 90 days, analysts recorded 0 upgrades, 8 maintains, and 0 downgrades.
How BestStocks tracks LH
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared LH-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for LH, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.